Table 1.
Clinical data for included patients.
| Variables | Patients (n=458) | No. of events (%) | MST (days) | HR (95% CI) | Log-rank P |
|---|---|---|---|---|---|
| Race | 0.004 | ||||
| White | 435 | 208 (47.8%) | 2454 | Ref. | |
| Others | 13 | 8 (61.5%) | 636 | 0.348 (0.171-0.709) | |
| Gender | 0.278 | ||||
| Male | 284 | 146 (51.4%) | 2454 | Ref. | |
| Female | 174 | 72 (41.4%) | 2030 | 0854 (0.642-1.136) | |
| Age (years) | 0.001 | ||||
| ≥60 | 219 | 102 (46.6%) | 1860 | Ref. | |
| <60 | 239 | 116 (48.3%) | 3564 | 0.620 (0.470-2.136) | |
| Tumor stage | 0.001 | ||||
| 0+I+II+I/II nos | 231 | 108 (46.8%) | 3259 | Ref. | |
| III+IV | 191 | 91 (47.6%) | 1960 | 0.600 (0.449-0.802) | |
| Missing | 36 |
Abbreviations: PSME, proteasome activator subunit; MST, median survival time; HR, hazard ratio; CI, confidence interval.